A good start of immunotherapy in esophageal cancer
Open Access
- 23 June 2019
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 8 (10) , 4519-4526
Abstract
Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the application of immunotherapy such as immune checkpoint inhibitors, peptide vaccine, adoptive T cell transfer and oncolytic virus in esophageal cancer. Some already have preliminary results and show the advantages of immunotherapy in esophageal cancer, while others are still in progress. This review aims to introduce the feasibility and current status of immunotherapy in esophageal cancer.Keywords
Funding Information
- Research and Development Program of Shandong
- Province
This publication has 66 references indexed in Scilit:
- Cancer classification using the Immunoscore: a worldwide task forceJournal of Translational Medicine, 2012
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensJournal of Translational Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survivalProceedings of the National Academy of Sciences, 2009
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patientsInternational Journal of Cancer, 2007
- Cancer Immunotherapy: A Treatment for the MassesScience, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003